2030 Compounding Pharmaceutical Companies 
European Pharmaceutical Review
OCTOBER 7, 2022
billion by 2030, displaying a compound annual growth rate (CAGR) of 6.0 The rising requirement for small-scale and encapsulated manufacturing processes necessary to assemble these products make it challenging for many pharmaceutical companies to alter their currently installed capacity.
European Pharmaceutical Review
AUGUST 17, 2022
billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.2 Pharmaceutical companies globally are significantly investing in R&D. percent between 2022 and 2030 (the forecast period) due to the growing demand for new drugs to tackle the high disease burden worldwide.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Patent Watch
DECEMBER 10, 2024
The Rise of Integrated CDMOs The global biotechnology and pharmaceutical services outsourcing market size was valued at $70.48 billion in 2022 and is expected to grow at a compound annual growth rate of 5.3% from 2023 to 2030.
Express Pharma
MAY 30, 2024
According to GlobalData’s Pharmaceutical Intelligence Center, Eisai’s Aricept has generated $188 million globally in 2023, and Leqembi is expected to become the dominant drug in neurology, with global sales forecasted to rise from $372 million in 2024 to $7.3 billion in 2030, with a compound annual growth rate (CAGR) of 117.6
European Pharmaceutical Review
FEBRUARY 3, 2023
The facility forms two new fully-automated production lines for liquid and freeze-dried drugs, including highly potent compounds and advanced therapies such as antibody drug conjugates (ADCs). Positively, it comes at a time when securing fill finish capacity can be a challenge for many pharmaceutical companies.
European Pharmaceutical Review
APRIL 3, 2024
Research by Roots Analysis predicts the pharmaceutical contract manufacturing market will value $140 billion by 2030. As such, the sector is expected to grow at a compounded annual growth rate (CAGR) of 6.5 percent between 2022-2030. Yet large companies are set to expand the market at a higher CAGR of 9.1
Express Pharma
OCTOBER 16, 2024
The CRO sector in India, growing at a compound annual growth rate (CAGR) of 10.75 billion by 2030 (2). Similarly, India’s pharmaceutical contract manufacturing market is expected to increase at a CAGR of 14.67 per cent, is projected to reach $2.5 per cent, hitting $44.63 billion by 2029 (3).
Expert insights. Personalized for you.
98 
Let's personalize your content